financetom
Business
financetom
/
Business
/
Solid Biosciences Grants Capsid AAV-SLB101 License to Andelyn Biosciences
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Solid Biosciences Grants Capsid AAV-SLB101 License to Andelyn Biosciences
Nov 17, 2025 7:51 AM

10:26 AM EST, 11/17/2025 (MT Newswires) -- Solid Biosciences ( SLDB ) said Monday it has entered into a non-exclusive worldwide license and collaboration agreement with Andelyn Biosciences for the use of Solid's capsid AAV-SLB101.

Solid said it grants Andelyn a license to provide its gene therapy clients with access to utilize the capsid in combination with Andelyn's suspension and adherent modular platform process.

Financial terms of the agreement were not disclosed.

Andelyn is a cell and gene therapy contract development and manufacturing organization. AAV-SLB101 is developed for enhanced skeletal muscle and cardiac tropism and reduced biodistribution to the liver, Solid said.

Shares were up about 6% in recent trading.

Price: 4.50, Change: +0.26, Percent Change: +6.13

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved